Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
42 hedge funds and large institutions have $90.6M invested in Oncternal Therapeutics, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 2 closing their positions.
850% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 2
157% more capital invested
Capital invested by funds: $35.3M → $90.6M (+$55.3M)
68% more funds holding
Funds holding: 25 → 42 (+17)
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$16.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.7M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$5.63M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.72M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$7.92M |
| 2 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$214K |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$107K |
| 4 |
BlackRock
New York
|
-$31.2K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$26.7K |
ONCT Hedge Fund Activity: Q1 2018 in Review
42 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q1 2018, worth a combined $90.6M — up 157% from $35.3M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ONCT positions and 2 closed out — a net gain of 17 holders — while 9 added to existing stakes and 7 trimmed.
The largest buyer was Boxer Capital, adding an estimated $16.3M. The largest seller was BVF Inc, cutting an estimated $7.92M.
- 42 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q1 2018, up from 25 in Q4 2017.
- Funds reported $90.6M of Oncternal Therapeutics, Inc. Common Stock stock for Q1 2018, up 157% quarter-over-quarter.
- 19 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q1 2018 and 2 closed out, a net change of +17 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q1 2018 was Boxer Capital, an estimated $16.3M added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q1 2018 was BVF Inc, an estimated $7.92M sold.
Based on aggregated 13F filings for Q1 2018.